Trials / Completed
CompletedNCT06612489
Efficacy of Biofeedback-Based Serious Game for Pain Alleviation in Middle-Aged and Older Ovarian Cancer Patients: A Randomized Controlled Trial
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- Shanghai Jiao Tong University School of Medicine · Academic / Other
- Sex
- Female
- Age
- 45 Years
- Healthy volunteers
- Not accepted
Summary
Consistent pain affects most middle-aged and older ovarian cancer patients. Non-pharmacological pain interventions, such as serious games, offer a promising approach to alleviating this pain by providing an effective sense of immersion. However, current games on the pain alleviation lack examination of its efficacy in middle-aged and older population and real-time monitoring of immersion level, particular since immersion level is highly associated with pain alleviation effect and adjustable to challenging level of game difficulty. This study developed a serious game with biofeedback-driven dynamic difficulty. Then examined its feasibility and efficacy through a two-arm, single-blinded randomized controlled trial. A total of 52 participants were recruited and randomized into intervention group and control group to receive biofeedback-based dynamic-difficulty serious game or fix-difficulty serious game for 15 mins each, respectively. The primary outcome was the assessment of the pain level, measured using the Visual Analog Scale. The secondary outcomes included pain-related anxiety, immersion level, and user experience.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | biofeedback based dynamic-difficulty game | A biofeedback based dynamic-difficulty serious game rooted in distraction therapy. |
| DEVICE | fixed difficulty game | A fixed difficulty serious game rooted in distraction therapy. |
Timeline
- Start date
- 2023-08-01
- Primary completion
- 2023-09-01
- Completion
- 2024-01-01
- First posted
- 2024-09-25
- Last updated
- 2024-09-25
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06612489. Inclusion in this directory is not an endorsement.